Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.41 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20876256 | 0.86 | MEN1 (0.41) | POLBNPC1CASP6ALOX12GAA | |
| SCHEMBL20876287 | 0.79 | NEU3 (0.36) | IP6K1IP6K3IP6K2POLBBRD4 | |
| SCHEMBL20887078 | 0.78 | KDM4E (0.39) | POLBNR4A2PLK1GALR3 | |
| SCHEMBL11619992 | 0.74 | POLB (0.43) | POLBNPC1CASP6ALOX15ALOX12 | |
| SCHEMBL11355098 | 0.74 | PTPN1 (0.53) | POLBNPC1ALOX15ALOX12 | |
| SCHEMBL11621890 | 0.71 | GPR35 (0.41) | POLBNPC1ALOX15ALOX12 | |
| SCHEMBL11364286 | 0.71 | GPR35 (0.46) | POLBNPC1ALOX15ALOX12 | |
| SCHEMBL10547068 | 0.70 | HNF4A (0.50) | POLBNPC1NR4A2PIM1GALR3 | |
| SCHEMBL10727346 | 0.69 | CHEK1 (0.40) | IP6K1IP6K3IP6K2NPC1CHEK1 | |
| SCHEMBL11620715 | 0.69 | POLB (0.59) | IP6K1IP6K3IP6K2POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3692026-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068783-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRPF3 | IP6K1 3222/4885IP6K3 2940/4885IP6K2 3103/4885 |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | BRD4, BRD3, BRPF3 | IP6K1 3222/4885IP6K3 2940/4885IP6K2 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.